Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
1996-11-19
2001-02-20
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001690, C424S130100, C424S155100, C424S133100, C424S138100, C424S141100, C424S152100, C424S156100, C424S172100, C424S174100
Reexamination Certificate
active
06190640
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a method of reducing the effects of colon cancer tumors, utilizing at least one monoclonal antibody. Specifically, at least one monoclonal antibody is utilized in conjunction with an anti-tumor drug, a peptide which inhibits DNA tumor activity or a radioisotope in the treatment of colorectal carcinoma. This invention further relates to a method of delivering genetic material to DNA of tumor cells and to a method of delivering anti-cancer agents to nuclei of colon tumor cells, as well as to monoclonal antibodies which are specific for A33 antigen; an antigen found on colon cancer cells.
BACKGROUND OF THE INVENTION
Colorectal carcinoma is a malignant neoplastic disease. There is a high incidence of colorectal carcinoma in the Western world, particularly in the United States. Tumors of this type often metastasize through lymphatic and vascular channels. Many patients with colorectal carcinoma eventually die from this disease. In fact, it is estimated that 62,000 persons in the United States alone die of colorectal carcinoma annually.
To date, systemic therapies and chemotherapies have been developed for the treatment of colorectal cancer. However, no therapies have exhibited sufficient anti-tumor activity to prolong the survival of colorectal carcinoma patients with metastatic disease with any degree of reliability. As a result, a need still exists to develop methods for the successful treatment of colorectal carcinoma.
It is therefore an object of this invention to provide methods for reducing the effects of colon cancers.
It is another object of this invention to provide a method of delivering genetic material to DNA of colon cancer cells.
It is a further object of this invention to provide a method of delivering anti-cancer agents to nuclei of colon cancer cells.
It is a still further object of this invention to provide antibodies, including monoclonal antibodies, humanized antibodies, chimeric antibodies, trimeric antibodies, heteromeric antibodies and single chain antibodies which are useful in the treatment of colon cancer.
SUMMARY OF THE INVENTION
This invention is directed to methods of reducing the effects of colon cancer comprising the administration of tumor-associated antibody conjugates. Specifically, at least one conjugate of an antibody which is associated with colon cancer cells and an anti-cancer drug is administered. Alternatively, at least one conjugate of an antibody which is specific for colon cancer cells and a peptide which inhibits DNA activity of said cells is administered in a pharmaceutically effective amount so as to reduce the effects of colon cancer. Another method of reducing the effects of colon cancer comprises administering a pharmaceutically effective amount of at least one conjugate of an antibody which is specific for said tumor and a radioisotope.
This invention is further directed to a method of delivering genetic material to colon cancer cells comprising contacting tumor cells with genetic material conjugated to an antibody which is internalized into the tumor cells, thereby mediating integration of genetic material into DNA.
In addition, anti-cancer agents can be delivered to the nuclei (DNA) of colon cancer cells by contacting the cells with an anti-cancer agent conjugated to an antibody which is internalized into said cells.
This invention is also directed to antibodies, including monoclonal, humanized, chimeric, trimeric, heteromeric and single chain antibodies, which can be utilized to reduce the effects of colon cancers.
REFERENCES:
patent: 5643550 (1997-07-01), Welt et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5968770 (1999-10-01), Falb et al.
patent: 94/13805 (1994-06-01), None
Gavin -Chesa et al (Intl, J. Oncol. 9/3 465-471, 1996.
Bennet, (Neurotranmitter Receptor Binding, Yamamura et al, eds Raven Press, NY p. 59, 1978.
Welt et al (Proc. An Meet, AM. Soc. Clin. Oncol, 11: A489, 1992.
Cohen Leonard
John Mary
Old Lloyd J.
Richards Elizabeth Carswell
Ritter Gerd
Fulbright & Jaworiski, LLP
Ludwig Institute for Cancer Research
Ungar Susan
LandOfFree
Method for treating neoplasia using humanized antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating neoplasia using humanized antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating neoplasia using humanized antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2604670